[1]
Kenney C., Kuo S.H., Jimenez-Shahed J.: Tourette’s syndrome. Am Fam
Physician 2008; 77: 651–658.
[1]
Kenney C., Kuo S.H., Jimenez-Shahed J.: Tourette’s syndrome. Am Fam
Physician 2008; 77: 651–658.
[2]
Hirtz D., Thurman D.J., Gwinn-Hardy K., et al.: How common are the
“common” neurologic disorders? Neurology 2007; 68: 326–337.
[2]
Hirtz D., Thurman D.J., Gwinn-Hardy K., et al.: How common are the
“common” neurologic disorders? Neurology 2007; 68: 326–337.
[3]
Bolch M.H., Sukhodolsky D.G., Leckman J.F., et al.: Fine-motor
skill deficits in childhood predict adulthood tic severity and global
psychosocial functioning in Tourette’s syndrome. J Child Psychol
Psychiatry 2006; 47: 551–559.
[3]
Bolch M.H., Sukhodolsky D.G., Leckman J.F., et al.: Fine-motor
skill deficits in childhood predict adulthood tic severity and global
psychosocial functioning in Tourette’s syndrome. J Child Psychol
Psychiatry 2006; 47: 551–559.
[4]
Leckman J.F.: Phenomenology of tics and natural history of tic disorders.
Brain Dev 2003; 25: 24–28.
[4]
Leckman J.F.: Phenomenology of tics and natural history of tic disorders.
Brain Dev 2003; 25: 24–28.
[5]
Li A.Y., Cong S., Lu H., et al.: Clinical observation on treatment of Tourette
Syndrome by integrative medicine. Chin J Integr Med 2009; 15: 261–
265.
[5]
Li A.Y., Cong S., Lu H., et al.: Clinical observation on treatment of Tourette
Syndrome by integrative medicine. Chin J Integr Med 2009; 15: 261–
265.
[6]
Bloch M.H., Peterson B.S., Scahill L., et al.: Adulthood outcome of tic
and obsessive-compulsive symtom severity in children with Tourette
syndrome. Arch Pediatr Adolesc Med 2006; 160: 65–69.
[6]
Bloch M.H., Peterson B.S., Scahill L., et al.: Adulthood outcome of tic
and obsessive-compulsive symtom severity in children with Tourette
syndrome. Arch Pediatr Adolesc Med 2006; 160: 65–69.
[7]
Bolch M.H., Sukhodolsky D.G., Leckman J.F.: Fine-motor skill deficits
in childhood predict adulthood tic severity and global psychosocial
functioning in Tourette’s syndrome. J Child Psychol Psychiatry 2006; 47:
551–559.
[7]
Bolch M.H., Sukhodolsky D.G., Leckman J.F.: Fine-motor skill deficits
in childhood predict adulthood tic severity and global psychosocial
functioning in Tourette’s syndrome. J Child Psychol Psychiatry 2006; 47:
551–559.
[8]
Leckman J.F., Bloch M.H., Scahill L., et al.: Tourette syndrome: the self
under siege. J child Neurol 2006; 21: 642–649.
[8]
Leckman J.F., Bloch M.H., Scahill L., et al.: Tourette syndrome: the self
under siege. J child Neurol 2006; 21: 642–649.
[9]
Bloch M.H., Leckman J.F.: Clinical course of Tourette syndrome. J
Psychosom Res 2009; 67: 497–501.
[9]
Bloch M.H., Leckman J.F.: Clinical course of Tourette syndrome. J
Psychosom Res 2009; 67: 497–501.
[10]
Wood D.W., Piacentini J., Himle MB., et al.: Premonitory Urge for
Tics Scale(PUTS): initial psychometric results and examination of the
premonitory urge phenomenon in youth with Tic disorders. J Dev Behav
Pediatr. 2005; 26: 397–403.
[10]
Wood D.W., Piacentini J., Himle MB., et al.: Premonitory Urge for
Tics Scale(PUTS): initial psychometric results and examination of the
premonitory urge phenomenon in youth with Tic disorders. J Dev Behav
Pediatr. 2005; 26: 397–403.
[11]
Bloch M.H.: Emerging treatment for Tourette’s disorder. Curr Psychiatry
Rep 2008; 10: 323–330.
[11]
Bloch M.H.: Emerging treatment for Tourette’s disorder. Curr Psychiatry
Rep 2008; 10: 323–330.
[12]
Robertson M.M., Eapen V., Cavanna AE., et al.: The international
prevalence, epidemiology and clinical phenomenology of Tourette
syndrome: a cross-culture perspective. J Psychosom Res 2009; 67:
475–483.
[12]
Robertson M.M., Eapen V., Cavanna AE., et al.: The international
prevalence, epidemiology and clinical phenomenology of Tourette
syndrome: a cross-culture perspective. J Psychosom Res 2009; 67:
475–483.
[13]
Vicario C.M., Martino D., Spata F., et al.: Time processing in children with
Tourette’s syndrome. Brain Cogn 2010; 73: 28–34.
[13]
Vicario C.M., Martino D., Spata F., et al.: Time processing in children with
Tourette’s syndrome. Brain Cogn 2010; 73: 28–34.
[14]
Gorman D.A., Thompson N., Plessen K.J., et al.: Psychosocial outcome
and psychiatric comorbidity in older adolescents with Tourette
syndrome: controlled study. Br J Psychiatry 2010; 197: 36–44.
[14]
Gorman D.A., Thompson N., Plessen K.J., et al.: Psychosocial outcome
and psychiatric comorbidity in older adolescents with Tourette
syndrome: controlled study. Br J Psychiatry 2010; 197: 36–44.
[15]
Muller-Vahik, Dodel I., Muller N., et al.: Health-related quality of life in
patients with Gilles de la Tourette’s syndrome. Mov Disord 2010; 25:
309–314.
[15]
Muller-Vahik, Dodel I., Muller N., et al.: Health-related quality of life in
patients with Gilles de la Tourette’s syndrome. Mov Disord 2010; 25:
309–314.
[16]
Cavanna A.E., Eddy C., Rickards HE.: Cognitive functioning in Tourette
syndrome. Discove Med 2009; 8: 191–195.
[16]
Cavanna A.E., Eddy C., Rickards HE.: Cognitive functioning in Tourette
syndrome. Discove Med 2009; 8: 191–195.
[17]
Młodzikowska-Albrecht J., Żarowski M., Steinborn B.: Sleep disorders in
Tourette syndrome in children and adolescents. Neurol Dziec 2010; 19:
39–42.
[17]
Młodzikowska-Albrecht J., Żarowski M., Steinborn B.: Sleep disorders in
Tourette syndrome in children and adolescents. Neurol Dziec 2010; 19:
39–42.
[18]
Kimber T.E.: An update on Tourette syndrome. Curr Neurol Neurosci Rep.
2010; 10: 286–291.
[18]
Kimber T.E.: An update on Tourette syndrome. Curr Neurol Neurosci Rep.
2010; 10: 286–291.
[19]
Dehning S., Muller N., Matz J., et al.: A genetic variant of HTR2C may
play a role in the manifestation of Tourette syndrome. Psychiatr Genet
2010; 20: 35–38.
[19]
Dehning S., Muller N., Matz J., et al.: A genetic variant of HTR2C may
play a role in the manifestation of Tourette syndrome. Psychiatr Genet
2010; 20: 35–38.
[20]
Riviere J.B., St-Onge, Gaspar C., et al.: Genome-wide TDT analysis in
French-Canadian families with Tourette syndrome. Can J Neurol Sci
2010; 37: 110–112.
[20]
Riviere J.B., St-Onge, Gaspar C., et al.: Genome-wide TDT analysis in
French-Canadian families with Tourette syndrome. Can J Neurol Sci
2010; 37: 110–112.
[21]
Davila G., Berthier M.L., Kulisevsky J., et al.: Structural abnormalities
in the substantia nigra and neighbouring nuclei in Tourette syndrome. J
Neural Transm 2010; 117: 481–488 .
[21]
Davila G., Berthier M.L., Kulisevsky J., et al.: Structural abnormalities
in the substantia nigra and neighbouring nuclei in Tourette syndrome. J
Neural Transm 2010; 117: 481–488 .
[22]
Tobe R.H., Bansal R., Xu D., et al.: Cerebellar morphology in Tourette
syndrome and obsessive disorder. Ann Neurol 2010; 67: 479–487.
[22]
Tobe R.H., Bansal R., Xu D., et al.: Cerebellar morphology in Tourette
syndrome and obsessive disorder. Ann Neurol 2010; 67: 479–487.
[23]
Motlagh M.G., Katsovich L., Thompson N., et al.: Severe psychosocial
stress and heavy cigarette smoking during pregnancy: an examination
of the pre-and perinatal risk factors associated with ADHD and Tourette
Syndrome. Eur. Child Adolesc Psychiatry 2010; 19: 795–764.
[23]
Motlagh M.G., Katsovich L., Thompson N., et al.: Severe psychosocial
stress and heavy cigarette smoking during pregnancy: an examination
of the pre-and perinatal risk factors associated with ADHD and Tourette
Syndrome. Eur. Child Adolesc Psychiatry 2010; 19: 795–764.
[24]
Taylor J.L., Rajbhandari A.K., Berridge K.C., et al.: Dopamine receptor
modulation of repetitive grooming action in the rat: potential relevance
for Tourette syndrome. Brain Res 2010; 1332: 92–101.
[24]
Taylor J.L., Rajbhandari A.K., Berridge K.C., et al.: Dopamine receptor
modulation of repetitive grooming action in the rat: potential relevance
for Tourette syndrome. Brain Res 2010; 1332: 92–101.
[25]
Lv H., Li A., Liu F., et al.: Effects of gastrodin on the dopamine system of
Tourette’s syndrome rat models. Bioscl Trends 2009; 3: 58–62.
[25]
Lv H., Li A., Liu F., et al.: Effects of gastrodin on the dopamine system of
Tourette’s syndrome rat models. Bioscl Trends 2009; 3: 58–62.
[26]
Steeves T.D., Ko J.H., Kideckel D.M., et al.: Extrastriatal dopaminergic
dysfunction in Tourette syndrome. Ann Neurol 2010; 67: 170–181.
[26]
Steeves T.D., Ko J.H., Kideckel D.M., et al.: Extrastriatal dopaminergic
dysfunction in Tourette syndrome. Ann Neurol 2010; 67: 170–181.
[27]
Janik P., Kalbarczyk A., Gutowicz M., et al.: The analysis of selected
neurotransmitter concentration in serum of patients with Tourette
syndrome. Neurol Neurochir Pol 2010; 44: 251–259.
[27]
Janik P., Kalbarczyk A., Gutowicz M., et al.: The analysis of selected
neurotransmitter concentration in serum of patients with Tourette
syndrome. Neurol Neurochir Pol 2010; 44: 251–259.
[28]
Ercan-Sencicek A.G., Stillman A.A., Ghosh AK., et al.: L-histidine
decarboxylase and Tourette’s syndrome. N Engl J Med 2010; 362:
1901–1908.
[28]
Ercan-Sencicek A.G., Stillman A.A., Ghosh AK., et al.: L-histidine
decarboxylase and Tourette’s syndrome. N Engl J Med 2010; 362:
1901–1908.
[29]
Sandor P.: Pharmacological management of tics in patients with TS. J
Psychosom Res 2003; 55: 44–48.
[29]
Sandor P.: Pharmacological management of tics in patients with TS. J
Psychosom Res 2003; 55: 44–48.
[30]
Swerdlow N.R., Bongiovanni M.J., Tochen L., et al.: Separable
noradrenergic and dopaminergic regulation of prepulse inhibition
in rats: implication for predictive validity and Tourette syndrome.
Psychopharmacology (Berl.) 2006; 186: 246–254.
[30]
Swerdlow N.R., Bongiovanni M.J., Tochen L., et al.: Separable
noradrenergic and dopaminergic regulation of prepulse inhibition
in rats: implication for predictive validity and Tourette syndrome.
Psychopharmacology (Berl.) 2006; 186: 246–254.
[31]
Hedderick E.F., Morris C.M., Singer HS.: Double-blind, crossover study of
clonidine and levetiracetam in Tourette syndrome. Pediatr Neurol 2009;
40: 420–425.
[31]
Hedderick E.F., Morris C.M., Singer HS.: Double-blind, crossover study of
clonidine and levetiracetam in Tourette syndrome. Pediatr Neurol 2009;
40: 420–425.
[32]
Du Y.S., Li H.F., Vance A., et al.: A randomized, double-blind, multi-center,
placebo-controlled clinical trial of the clonidine adhesive patch for the
treatment of tic disorders. Australian and New-Zealand J. Psychiatry
2008; 42: 807–813.
[32]
Du Y.S., Li H.F., Vance A., et al.: A randomized, double-blind, multi-center,
placebo-controlled clinical trial of the clonidine adhesive patch for the
treatment of tic disorders. Australian and New-Zealand J. Psychiatry
2008; 42: 807–813.